Antiangiogenic gene therapy of experimental pancreatic tumor by sFlt-1 plasmid DNA carried by RGD-modified crosslinked polyplex micelles

Journal of Controlled Release

Volumn 149, Issue 1, 2011, Pages 51-57

  Vachutinsky, Yelena ^a   Oba, Makoto ^b   Miyata, Kanjiro ^b   Hiki, Shigehiro ^a   Kano, Mitsunobu R ^b   Nishiyama, Nobuhiro ^a,b   Koyama, Hiroyuki ^b   Miyazono, Kohei ^a,b   Kataoka, Kazunori ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Antiangiogenic gene therapy; Cyclic RGD peptide; Poly(ethylene glycol) block poly(l lysine) (PEG PLys); Polyplex micelle; sFlt 1

Indexed keywords

ANTIANGIOGENIC; ANTIANGIOGENIC GENE THERAPY; COMBINED EFFECT; CROSS-LINKED MICELLES; CROSSLINKED; DENSITY MEASUREMENTS; INHIBITION OF TUMOR GROWTH; INTRACELLULAR UPTAKE; ION COMPLEXATION; L-LYSINE; PANCREATIC ADENOCARCINOMA; PANCREATIC TUMORS; PLASMID DNA; POLYPLEXES; RECEPTOR-MEDIATED ENDOCYTOSIS; RGD PEPTIDE; SFLT-1; THERAPEUTIC ACTIVITY; THERAPEUTIC EFFECTS; TUMOR ACCUMULATION;

AMINO ACIDS; BIOMOLECULES; COMPLEXATION; DNA; ENDOTHELIAL CELLS; ETHYLENE; ETHYLENE GLYCOL; GENETIC ENGINEERING; MICELLES; PEPTIDES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; TUMORS;

GENE THERAPY;

ARGINYLGLYCYLASPARTIC ACID; MACROGOL; PLASMID DNA; POLYLYSINE; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEX FORMATION; CROSS LINKING; DRUG EFFECT; ENDOCYTOSIS; FEMALE; GENE THERAPY; MICELLE; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TUMOR; CROSS-LINKING REAGENTS; DNA; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; INJECTIONS, INTRAVENOUS; LYSINE; MICE; MICE, INBRED BALB C; MICELLES; MICROVESSELS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PANCREATIC NEOPLASMS; PEPTIDES, CYCLIC; PLASMIDS; POLYETHYLENE GLYCOLS; POLYLYSINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFHYDRYL COMPOUNDS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 78651244521     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.02.002     Document Type: Article

References (42)

1. A. Harada, and K. Kataoka Formation of polycation complex micelles in an aqueous milieu from a pair of oppositely-charged block copolymers with poly(ethylene glycol) segments Macromolecules 28 15 1995 5294 5299
2. S. Katayose, and K. Kataoka Water-soluble polyion complex associates of DNA and poly(ethylene glycol)-poly(l-lysine) block copolymer Bioconjug. Chem. 8 5 1997 702 707 (Pubitemid 27416084)
3. M. Harada-Shiba, K. Yamauchi, A. Harada, I. Takamisawa, K. Shimokado, and K. Kataoka Polyion complex micelles as vectors in gene therapy - pharmacokinetics and in vivo gene transfer Gene Ther. 9 6 2002 407 414
4. M. Laus, K. Sparnacci, B. Ensoli, S.O. Buttò, A. Caputo, I. Mantovani, G. Zuccheri, B. Samorì, and L. Tondelli Complex associates of plasmid DNA and a novel class of block copolymers with PEG and cationic segments as new vectors for gene delivery J. Biomater. Sci. Polym. Ed. 12 2 2001 209 228
5. C.H. Ahn, S.Y. Chae, Y.H. Bae, and S.W. Kim Synthesis of biodegradable multi-block copolymers of poly(l-lysine) and poly(ethylene glycol) as a non-viral gene carrier J. Control. Release 97 3 2004 567 574
6. Y. Wang, C.Y. Ke, B.C. Weijie, S.Q. Liu, S.H. Goh, and Y.Y. Yang The self-assembly of biodegradable cationic polymer micelles as vectors for gene transfection Biomaterials 28 35 2007 5358 5368 (Pubitemid 47532189)
7. Y.R. Choi, S.Y. Chae, C.H. Ahn, M. Lee, S. Oh, Y. Byun, B.D. Rhee, and K.S. Ko Development of polymeric gene delivery carriers: PEGylated copolymers of l-lysine and l-phenylalanine J. Drug Target. 15 6 2007 391 398
8. K. Itaka, K. Yamauchi, A. Harada, K. Nakamura, H. Kawaguchi, and K. Kataoka Polyion complex micelles from plasmid DNA and poly(ethylene glycol)-poly(l-lysine) block copolymer as serum-tolerable polyplex system: physicochemical properties of micelles relevant to gene transfection efficiency Biomaterials 24 24 2003 4495 4506
9. S. Mishra, P. Webster, and M.E. Davis PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles Eur. J. Cell Biol. 83 3 2004 97 111
10. A.M. Funhoff, S. Monge, R. Teeuwen, G.A. Koning, N.M. Schuurmans-Nieuwenbroek, D.J. Crommelin, D.M. Haddleton, W.E. Hennink, and C.F. van Nostrum PEG shielded polymeric double-layered micelles for gene delivery J. Control. Release 102 3 2005 711 724
11. H.K. de Wolf, C.J. Snel, F.J. Verbaan, R.M. Schiffelers, W.E. Hennink, and G. Storm Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration Int. J. Pharm. 331 2 2007 167 175
12. K. Miyata, Y. Kakizawa, N. Nishiyama, A. Harada, Y. Yamasaki, H. Koyama, and K. Kataoka Block catiomer polyplexes with regulated densities of charge and disulfide cross-linking directed to enhance gene expression J. Am. Chem. Soc. 126 8 2004 2355 2361
13. K. Miyata, Y. Kakizawa, N. Nishiyama, Y. Yamasaki, T. Watanabe, M. Kohara, and K. Kataoka Freeze-dried formulations for in vivo gene delivery of PEGylated polyplex micelles with disulfide crosslinked cores to the liver J. Control. Release 109 1-3 2005 15 23
14. 5 integrins Bioconjug. Chem. 18 5 2007 1415 1423
15. M. Oba, K. Aoyagi, K. Miyata, Y. Matsumoto, K. Itaka, N. Nishiyama, Y. Yamasaki, H. Koyama, and K. Kataoka Polyplex Micelles with cyclic RGD peptide ligands and disulfide cross-links directing to the enhanced transfection via controlled intracellular trafficking Mol. Pharmaceutics 5 6 2008 1080 1092
16. M.D. Pierschbacher, and E. Ruoslahti Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule Nature 309 5963 1984 30 33
17. 3 antagonists J. Am. Chem. Soc. 118 1996 7461 7472
18. A. Erdreich-Epstein, H. Shimada, S. Groshen, M. Liu, L.S. Metelitsa, K.S. Kim, M.F. Stins, R.C. Seeger, and D.L. Durden Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide Cancer Res. 60 3 2000 712 721
19. R.M. Schiffelers, A. Ansari, J. Xu, Q. Zhou, Q. Tang, G. Storm, G. Molema, P.Y. Lu, P.V. Scaria, and M.C. Woodle Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle Nucleic Acids Res. 32 19 2004 e149
20. W.J. Kim, J.W. Yockman, M. Lee, J.H. Jeong, Y.H. Kim, and S.W. Kim Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis J. Control. Release 106 1-2 2005 224 234
21. W.J. Kim, J.W. Yockman, J.H. Jeong, L.V. Christensen, M. Lee, Y.H. Kim, and S.W. Kim Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice J. Control. Release 114 3 2006 381 388
22. K. Temming, R.M. Schiffelers, G. Molema, and R.J. Kok RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumor vasculature Drug Resist. Updat. 8 6 2005 381 402
23. K.A. Thomas Vascular endothelial growth factor, a potent and selective angiogenic agent J. Biol. Chem. 271 2 1996 603 606
24. G. Breier Functions of the VEGF/VEGF receptor system in the vascular system Semin. Thromb. Hemost. 26 5 2000 553 559
25. R.A. Brekken, and P.E. Thorpe VEGF-VEGF receptor complexes as markers of tumor vascular endothelium J. Control. Release 74 1-3 2001 173 181
26. A.L. Harris Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy Recent Results Cancer Res. 152 1998 341 352
27. N. Ferrara VEGF as a therapeutic target in cancer Oncology 69 2005 11 16
28. R.L. Kendall, G. Wang, and K.A. Thomas Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR Biochem. Biophys. Res. Commun. 226 2 1996 324 328
29. H. Chen, U. Ikeda, M. Shimpo, Y. Maeda, M. Shibuya, K. Ozawa, and K. Shimada Inhibition of vascular endothelial growth factor activity by transfection with the soluble FLT-1 gene J. Cardiovasc. Pharmacol. 36 4 2000 498 502
30. M. Malecki, H. Trembacz, B. Szaniawska, M. Przybyszewska, and P. Janik Vascular endothelial growth factor and soluble FLT-1 receptor interactions and biological implications Oncol. Rep. 14 6 2005 1565 1569
31. C. Ye, C. Feng, S. Wang, K.Z. Wang, N. Huang, X. Liu, Y. Lin, and M. Li sFlt-1 gene therapy of follicular thyroid carcinoma Endocrinology 145 2 2004 817 822
32. Y. Hasumi, H. Mizukami, M. Urabe, T. Kohno, K. Takeuchi, A. Kume, M. Momoeda, H. Yoshikawa, T. Tsuruo, M. Shibuya, Y. Taketani, and K. Ozawa Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer Cancer Res. 62 7 2002 2019 2023
33. G. Mahendra, S. Kumar, T. Isayeva, P.J. Mahasreshti, D.T. Curiel, C.R. Stockardt, W.E. Grizzle, V. Alapati, R. Singh, G.P. Siegal, S. Meleth, and S. Ponnazhagan Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor Cancer Gene Ther. 12 1 2005 26 34
34. Y. Takei, H. Mizukami, Y. Saga, I. Yoshimura, Y. Hasumi, T. Takayama, T. Kohno, T. Matsushita, T. Okada, A. Kume, M. Suzuki, and K. Ozawa Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector Int. J. Cancer 120 2 2007 278 284
35. S. Kommareddy, and M. Amiji Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors Cancer Gene Ther. 14 5 2007 488 498
36. M.R. Kano, Y. Komuta, C. Iwata, M. Oka, Y.T. Shirai, Y. Morishita, Y. Ouchi, K. Kataoka, and K. Miyazono Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature Cancer Sci. 100 1 2009 173 180
37. A. Harada, and K. Kataoka Formation of polyion complex micelles in an aqueous milieu from a pair of oppositely charged block copolymers with poly(ethylene glycol) segments Macromolecules 28 1995 294 299
38. P.K. Dubey, V. Mishra, S. Jain, S. Mahor, and S.P. Vyas Liposomes modified with cyclic RGD peptide for tumor targeting J. Drug Target. 12 5 2004 257 264
39. A.J. Schraa, R.J. Kok, H.E. Moorlag, E.J. Bos, J.H. Proost, D.K. Meijer, L.F. de Leij, and G. Molema Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study Int. J. Cancer 102 5 2002 469 475 (Pubitemid 35316000)
40. R.M. Schiffelers, G.A. Koning, T.L. ten Hagen, M.H. Fens, A.J. Schraa, A.P. Janssen, R.J. Kok, G. Molema, and G. Storm Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin J. Control. Release 91 1-2 2003 115 122
41. A. Mitra, J. Mulholland, A. Nan, E. McNeill, H. Ghandehari, and B.R. Line Targeting tumor angiogenic vasculature using polymer-RGD conjugates J. Control. Release 102 1 2005 191 201
42. D.C. Bibby, J.E. Talmadge, M.K. Dalal, S.G. Kurz, K.M. Chytil, S.E. Barry, D.G. Shand, and M. Steiert Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice Int. J. Pharm. 293 1-2 2005 281 290